Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Multiple Sclerosis

  Free Subscription


1 Acta Neurol Scand
1 Brain
1 Int J Neurosci
2 J Neuroimmunol
1 J Neurol
2 J Neurol Neurosurg Psychiatry
2 J Neurol Sci
1 Mult Scler
1 Nat Rev Neurol
1 Neurologia (Engl Ed)
1 Neurology
1 Rev Neurol (Paris)

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Acta Neurol Scand

  1. MAHAMUD Z, Burman J, Zelano J
    Temporal trends of epilepsy in multiple sclerosis.
    Acta Neurol Scand. 2022 Jul 18. doi: 10.1111/ane.13671.
    PubMed         Abstract available


  2. EISSMAN JM, Dumitrescu L, Mahoney ER, Smith AN, et al
    Sex differences in the genetic architecture of cognitive resilience to Alzheimer's disease.
    Brain. 2022 May 13. pii: 6585174. doi: 10.1093.
    PubMed         Abstract available

    Int J Neurosci

  3. KHORRAMI M, Saneipour M, Moridnia A, Shaygannejad V, et al
    Interdependency of NINJ2 gene expression and polymorphism with susceptibility and response to Interferon Beta in patients with Multiple Sclerosis.
    Int J Neurosci. 2022 Aug 1:1-9. doi: 10.1080/00207454.2022.2102979.
    PubMed         Abstract available

    J Neuroimmunol

  4. ALOISI F, Cross AH
    MINI-review of Epstein-Barr virus involvement in multiple sclerosis etiology and pathogenesis.
    J Neuroimmunol. 2022;371:577935.
    PubMed         Abstract available

  5. FUCHS L, Mausner-Fainberg K, Luban A, Asseyer SE, et al
    CTGF/CCN2 has a possible detrimental role in the inflammation and the remyelination failure in the early stages of multiple sclerosis.
    J Neuroimmunol. 2022;371:577936.
    PubMed         Abstract available

    J Neurol

  6. KREFT KL, Robertson NP
    Innovative biomarkers to predict unfavourable outcomes after initiating multiple sclerosis treatment.
    J Neurol. 2022 Aug 1. pii: 10.1007/s00415-022-11300.

    J Neurol Neurosurg Psychiatry

  7. CHEN J, Diouf I, Taylor BV, Kalincik T, et al
    Superior effects of natalizumab versus other DMTs on patient-reported outcomes in people with multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2022 Jul 28. pii: jnnp-2022-329223.
    PubMed         Abstract available

  8. KWON S, Jung SY, Han KD, Jung JH, et al
    Risk of Parkinson's disease in multiple sclerosis and neuromyelitis optica spectrum disorder: a nationwide cohort study in South Korea.
    J Neurol Neurosurg Psychiatry. 2022 Jul 28. pii: jnnp-2022-329389.
    PubMed         Abstract available

    J Neurol Sci

  9. HARIRCHIAN MH, Zahednasab H, Karampoor S
    The enigmatic role of macrophage inhibitory factor (MIF) in the pathogenesis of multiple sclerosis (MS).
    J Neurol Sci. 2022;440:120351.

  10. MERMELSTEIN M, Naftali J, Wilf-Yarkoni A, Lotan I, et al
    Repeated lumbar puncture in search of oligoclonal bands - What is the yield?
    J Neurol Sci. 2022;439:120298.
    PubMed         Abstract available

    Mult Scler

  11. TAGGE IJ, Leppert IR, Fetco D, Campbell JS, et al
    Permanent tissue damage in multiple sclerosis lesions is associated with reduced pre-lesion myelin and axon volume fractions.
    Mult Scler. 2022 Jul 28:13524585221110585. doi: 10.1177/13524585221110585.
    PubMed         Abstract available

    Nat Rev Neurol

  12. FILIPPI M, Preziosa P
    MRI predicts cognitive training effects in multiple sclerosis.
    Nat Rev Neurol. 2022 Aug 1. pii: 10.1038/s41582-022-00701.

    Neurologia (Engl Ed)

  13. BROCHE-PEREZ Y, Jimenez-Morales RM, Monasterio-Ramos LO, Vazquez-Gomez LA, et al
    Fear of Relapse Scale: Spanish version and psychometric characteristics in a sample of patients with Relapsing-Remitting Multiple Sclerosis.
    Neurologia (Engl Ed). 2022 Jul 27. pii: S2173-5808(22)00080.
    PubMed         Abstract available


  14. BSTEH G, Krajnc N, Riedl K, Altmann P, et al
    Retinal Layer Thinning After Optic Neuritis is Associated With Future Relapse Remission in Relapsing Multiple Sclerosis.
    Neurology. 2022 Aug 2. pii: WNL.0000000000200970.
    PubMed         Abstract available

    Rev Neurol (Paris)

  15. CHEDID T, Moisset X, Clavelou P
    Rationale for off-label treatments use in primary progressive multiple sclerosis: A review of the literature.
    Rev Neurol (Paris). 2022 Jul 15. pii: S0035-3787(22)00639.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.